HDFC MF and ADIA Lead ₹777 Crore Block Deal in Corona Remedies
A significant shift in the shareholding pattern of pharmaceutical player Corona Remedies Limited took place on June 17, 2026, as major institutional investors moved to acquire substantial stakes. The massive block deal saw marquee names like HDFC Mutual Fund and the Abu Dhabi Investment Authority (ADIA) entering the fray, signaling strong institutional confidence in the company.
Massive Divestment by Sepia Investments and Anchor Partners
The block deal was primarily driven by the exit of two major sellers. Sepia Investments offloaded 43,28,943 shares of Corona Remedies at a price of ₹1,730 per share, amounting to a deal value of approximately ₹748.9 crore. Adding to this volume, Anchor Partners divested 1,61,861 shares at the same price, contributing another ₹28 crore to the transaction. Combined, these two entities offloaded shares worth roughly ₹776.9 crore in the pharmaceutical company.
HDFC Mutual Fund Dominates the Buy Side
The absorption of these shares was led by a diverse group of twelve institutional investors. HDFC Mutual Fund emerged as the most aggressive buyer, acquiring 24,50,000 shares worth approximately ₹423.9 crore. This single transaction accounted for more than half of the total deal value, underscoring HDFC MF's significant conviction in the stock's future prospects.
Other prominent domestic and international players also participated heavily:
- Aditya Birla Sun Life Mutual Fund acquired 4,90,000 shares worth ₹84.8 crore.
- Invesco Mutual Fund picked up 2,89,017 shares, valued at around ₹50 crore.
- Kotak Mahindra Mutual Fund bought 1,61,861 shares, matching the exact quantity sold by Anchor Partners, worth ₹28 crore.
Global Institutional Interest in Corona Remedies
The deal also highlighted significant interest from global fund managers and sovereign wealth funds. Aberdeen Asian Smaller Companies Investment Trust Plc purchased 4,50,868 shares for approximately ₹78 crore, while the Aberdeen Standard Sicav I - Asian Smaller Companies Fund took up 2,74,132 shares worth ₹47.4 crore.
Darüber hinaus stieg die Abu Dhabi Investment Authority (ADIA) in die Cap Table ein, indem sie 39.130 Aktien im Wert von 6,8 Crore ₹ erwarb. Zu den weiteren internationalen Teilnehmern gehörten der WhiteOak Capital Mutual Fund, der 25,1 Crore ₹ investierte, und der India Acorn ICAV - Ashoka WhiteOak Emerging Markets Equity Fund, der Aktien im Wert von 25,7 Crore ₹ kaufte. Sogar kleinere Nischenakteure wie die Factory Mutual Insurance Company beteiligten sich und erwarben 10.670 Aktien im Wert von 1,9 Crore ₹.
Wichtigste Erkenntnisse
- Großer institutioneller Ausstieg: Sepia Investments und Anchor Partners stiegen mit einer kombinierten Position im Wert von etwa 776,9 Crore ₹ aus Corona Remedies aus.
- HDFC MF führt Käufe an: Der HDFC Mutual Fund war der Hauptkäufer und sicherte sich Aktien im Wert von 423,9 Crore ₹, was über 50 % des gesamten Transaktionswertes entspricht.
- Hohes institutionelles Vertrauen: Die Beteiligung globaler Akteure wie der ADIA und verschiedener Aberdeen-Fonds deutet auf ein starkes grenzüberschreitendes institutionelles Interesse am Pharmasektor hin.